4//SEC Filing
NEWHALL CHARLES W III 4
Accession 0001628280-25-044797
CIK 0001356576other
Filed
Oct 9, 8:00 PM ET
Accepted
Oct 10, 4:21 PM ET
Size
7.3 KB
Accession
0001628280-25-044797
Insider Transaction Report
Form 4
NEWHALL CHARLES W III
Director10% Owner
Transactions
- Sale
Common Stock
2025-10-09$51.55/sh−1,200$61,860→ 104,644 total - Sale
Common Stock
2025-10-09$50.73/sh−23,800$1,207,374→ 105,844 total
Footnotes (3)
- [F1]Transaction made pursuant to a 10b5-1 trading plan adopted March 3, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.12 to $51.08. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.39 to $51.76. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Documents
Issuer
SUPERNUS PHARMACEUTICALS, INC.
CIK 0001356576
Entity typeother
Related Parties
1- filerCIK 0001005544
Filing Metadata
- Form type
- 4
- Filed
- Oct 9, 8:00 PM ET
- Accepted
- Oct 10, 4:21 PM ET
- Size
- 7.3 KB